[ad_1] Image source: Getty Images If you rewind to five years ago, Lloyds (LSE: LLOY) shares closed the day on 11 June 2021 at a lowly 48.4p each. That means 10,000 of them could have been bought with £4,840. As…
[ad_1] Why Ares is more than a simple private-markets beta trade Ares Management (ARES) is often treated as a public-market proxy for enthusiasm around alternative assets. That view is too blunt. The better way to read Ares is as a…
[ad_1] Image source: Getty Images A Self-Invested Personal Pension (SIPP) is a long-term investment vehicle, given that many people hold the pension wrapper for decades before drawing out a single pound. That means it can be a natural fit for…
[ad_1] Why Bristol Myers is more than a patent-cliff story Bristol Myers Squibb is often reduced to a familiar big-pharma problem: legacy blockbusters lose exclusivity, revenue steps down, and the market waits to see whether the pipeline can plug the…
[ad_1] Image source: Getty Images UK investors have been piling into Broadcom (NASDAQ: AVGO) shares since they crashed (more than 20%) after its earnings report. Last week, they were among the most bought shares on AJ Bell. Is this a…
[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence ServiceNow shares tumbled 7.5% on Tuesday, closing at $105.68, as a broad selloff swept through the software sector and dragged down the enterprise application giant alongside its peers. The $109.0B company saw trading…
[ad_1] Image source: Getty Images We’re now over two months into the current Stocks and Shares ISA year. Even though there’s a cap of £20k that can be invested annually, it’s still a great tool that can be used to…
[ad_1] Introduction NVIDIA is still often valued and debated like a company riding one extraordinary product cycle in AI accelerators. Its latest primary disclosures suggest the story is already broader than that. The more durable thesis is that NVIDIA is…
[ad_1] Image source: Getty Images Building a second income through a Stocks and Shares ISA is one of the simplest ways I know to make investing work harder for you. On a steady £200 a month, and with dividends reinvested,…
[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence Protagonist Therapeutics surged 6.3% on Tuesday, riding a broad rally across biotechnology sector peers that lifted the company’s shares to $104.16. The Nasdaq-listed biotech closed with a market capitalization of $6.8 billion as…